AstraZeneca tweaks financial reporting; Spanish competition authority investigates Pfizer contracts;

@FiercePharma: Health Canada pledges more plant inspections and more transparency. More from FiercePharmaManufacturing | Follow @FiercePharma

@EricPFierce: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Novartis ($NVS) gets bragging rights on first U.S. biosim. But will its Neupogen copy sell? Story | Follow @CarlyHFierce

> AstraZeneca ($AZN) said it would change its financial reporting to make revenue from external ventures more visible to investors; the change won't affect its 2015 outlook, the company said. Report

> Spain's antitrust commission opened an investigation into Pfizer's ($PFE) unit there, saying its contracts and pricing may be hampering EU trade in pharmaceuticals; the U.S.-based drug giant lost a related appeal at the Spanish Supreme Court last month. Report | Report

> AbbVie ($ABBV) CEO Rick Gonzalez said a new form of Humira is "a fundamental change" in the drug's formulation and could help fight off generic erosion to the franchise when biosimilars appear. Report

> Catalyst Pharmaceuticals said the FDA had given breakthrough status to its drug Firdapse as a treatment for Congenital Myasthenic Syndromes, a rare neuromuscular disease. Release

Medical Device News

@FierceMedDev: Navidea joins forces with Norgine to market cancer imaging Dx in EU. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Now with ""s from OptiNose: Evidence that inhaled oxytocin improves social behavior among autistic patients spurs R&D. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: New superbug outbreak tied to endoscope devices surfaces amid FDA scrutiny. Article | Follow @EmilyWFierce

> EndoChoice raises $57M led by Deerfield to offer a better endoscopy view. News

> Johnson & Johnson ($JNJ) ordered to hand over $5.6M in vaginal mesh trial. More

Biotech News

@FierceBiotech: EuroBiotech: Billionaires plot Stallergenes merger, Cerenis set for IPO, Big Pharma-backed Opsona eyes IPO. Report | Follow @FierceBiotech

@JohnCFierce: You know Richard Gonzalez is sweating it out when he gives an interview like this ($ABBV). More from Reuters | Follow @JohnCFierce

@DamianFierce: "In 2009, $PCYC's shares fell to a record low 57 cents. $ABBV is paying cash and stock worth $261.25 a share." WSJ story | Follow @DamianFierce

> Novartis ($NVS) wins landmark approval for a biosimilar of Amgen's Neupogen. News

> Gates Foundation bets $52M on CureVac's mRNA promise. More

> Merck ($MRK) dumps 120 Cubist researchers after its $9.5B merger. Report

And Finally... Losing as little as half an hour of shuteye on weekdays may help trigger insulin resistance and obesity, a study found. Report